stockrow
Monday 9 November 2026
Export IPHA’s income statement to Excel — free account
Innate Pharma S.A. Sponsored ADR
IPHAInnate Pharma S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million, down 53.2% from fiscal 2024.
1.44
0.04
+2.86%
Follow IPHA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 59 | 39 | 111 | 96 | 80 | 29 | 61 | 67 | 22 | 10 | 93 | (17.7%) | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | +100.0 pt | ||||||
| EBT | 4 | (72) | 3 | (23) | (73) | (54) | (61) | (8) | (54) | (56) | (107) | n/m | ||||||
| EBT margin, % | 6.87 | (182.09) | 2.89 | (24.19) | (90.82) | (184.10) | (100.52) | (12.28) | (245.87) | (546.11) | (114.65) | (553.0) pt | ||||||
| Net income | 13 | 0 | 4 | (23) | (73) | (62) | (61) | (8) | (54) | (56) | (156) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 1.10 | 0.72 | 1.89 | 1.44 | 1.02 | 0.37 | 0.76 | 0.83 | 0.27 | 0.11 | 0.00 | (22.3%) | |||||
| Earnings | 0.24 | (1.07) | 0.06 | (0.35) | (0.93) | (0.78) | (0.77) | (0.10) | (0.66) | (0.62) | (1.17) | n/m | ||||||
| Cash flow | (0.72) | (1.04) | (0.65) | 0.58 | (0.75) | (0.87) | (0.25) | (0.44) | (0.09) | (0.67) | 0.00 | (0.9%) | ||||||
| Capex | 0.00 | 0.00 | (0.03) | (1.09) | (0.16) | (0.02) | (0.01) | (0.03) | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (0.72) | (1.04) | (0.68) | (0.51) | (0.91) | (0.89) | (0.27) | (0.47) | (0.10) | (0.67) | 0.00 | (0.9%) | ||||||
| Book value | 1.68 | 1.91 | 3.36 | 3.64 | 2.26 | 1.60 | 0.72 | 0.70 | 0.12 | (0.27) | 0.00 | n/m | ||||||
| Shares, m | 54 | 54 | 59 | 67 | 79 | 80 | 80 | 80 | 81 | 90 | — | +5.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 9.81 | 9.81 | 9.81 | 196.94 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.6 | |||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | 0.00 | 0.00 | 0.00 | 0.00 | (1.04) | (1.10) | (0.94) | (0.61) | (0.58) | (0.14) | 0.12 | (0.4) | ||||||
| EV/FCF | 0.00 | 0.00 | 0.00 | 0.00 | 7.31 | 0.38 | 0.49 | 0.83 | 1.01 | 0.13 | (0.08) | 1.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (39) | (56) | (38) | 39 | (59) | (69) | (20) | (35) | (7) | (60) | (127) | +4.9% | |||||
| Capex | (10) | (7) | (2) | (73) | (13) | (2) | (1) | (2) | 0 | 0 | (1) | (36.8%) | ||||||
| Free cash flow | (39) | (56) | (40) | (34) | (72) | (71) | (21) | (38) | (8) | (60) | (128) | +4.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 162 | 77 | 145 | 130 | 146 | 69 | 104 | 117 | 57 | 11 | (15) | (25.5%) | |||||
| Net debt | (204) | (134) | (193) | (224) | (151) | (89) | (62) | (57) | (54) | (13) | 11 | (26.2%) | ||||||
| Shareholders’ equity | 91 | 104 | 198 | 244 | 178 | 127 | 57 | 56 | 10 | (25) | (47) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 4.41 | (39.34) | 0.87 | (4.73) | (18.26) | (18.72) | (22.86) | (3.92) | (33.51) | (58.22) | 0.00 | (62.6) pt | |||||
| ROIC | 0.00 | 0.00 | 76.02 | (97.88) | (165.62) | (93.83) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 13.70 | (60.02) | 2.39 | (10.54) | (34.67) | (40.93) | (66.48) | (14.47) | (162.88) | 742.02 | 0.00 | +728.3 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 157 | 235 | 245 | 215 | 211 | 179 | 181 | 163 | — | +0.5% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.71 | 0.41 | 0.33 | 0.14 | 0.29 | 0.37 | 0.12 | 0.06 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · fundamentals updated 2 Nov 2026
Innate Pharma S.A. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PEPG PepGen, Inc. | $171.1M | — (loss-making) | — | — | n/m | +33.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CNTN Canton Strategic Holdings, Inc. | $164.1M | — (loss-making) | — | — | n/m | −600.39% (below 0%: shrinking) | 100.00% | (80.37%) | Compare |
| ZNTL Zentalis Pharmaceuticals, Inc. | $162.8M | — (loss-making) | — (loss-making) | — | n/m | −9.06% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IPHA Innate Pharma S.A. Sponsored ADR | $160.9M | — (loss-making) | — | +246.29% (above 0%: growing) | +106.08% (above 0%: growing) | −929.03% (below 0%: shrinking) | 0.00% | 0.00% | |
| ORMP Oramed Pharmaceuticals Inc. | $160.6M | 0.9× | 0.9× | +193.26% (above 0%: growing) | +493.75% (above 0%: growing) | +94.29% (above 0%: growing) | 0.65% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $159.7M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| STRO Sutro Biopharma, Inc. | $159.5M | — (loss-making) | — (loss-making) | −84.57% (below 0%: shrinking) | n/m | +14.55% (above 0%: growing) | 100.00% | (303.77%) | Compare |
| ANTX AN2 Therapeutics, Inc. | $150.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| INO Inovio Pharmaceuticals, Inc. | $125.6M | — (loss-making) | — (loss-making) | −83.19% (below 0%: shrinking) | n/m | +13.41% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $160.1M | — | — | −83.88% | — | +13.98% | 50.33% | 0.00% |